ProfileGDS5678 / 1418532_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 65% 66% 66% 65% 71% 65% 65% 66% 66% 66% 66% 66% 66% 66% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.9273665
GSM967853U87-EV human glioblastoma xenograft - Control 23.9689166
GSM967854U87-EV human glioblastoma xenograft - Control 33.9655766
GSM967855U87-EV human glioblastoma xenograft - Control 43.9447765
GSM967856U87-EV human glioblastoma xenograft - Control 54.452571
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.9783665
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.9650565
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.9508166
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.9526866
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.9472566
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.9558966
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.955766
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.966866
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.9496866